Badanie porównujące spersonalizowaną terapię podtrzymującą z rituksymabem i kortykosteroidami u pacjentów z pęcherzycą

Pemphigus is a group of rare skin diseases that cause blisters and sores on the skin and mucous membranes. The study focuses on two types of pemphigus: Pemphigus Vulgaris and Pemphigus Foliaceus. These conditions are characterized by the presence of antibodies that attack the skin cells, leading to painful blisters. The study aims to compare a personalized treatment approach with the standard treatment to see which is more effective in reducing the risk of the disease coming back over four years.

The standard treatment involves the use of rituximab, a medication given through an infusion into a vein, and corticosteroids, which are anti-inflammatory drugs. Rituximab works by targeting specific cells in the immune system that are involved in the disease process. The personalized treatment approach will use rituximab infusions based on the patient's risk of relapse, which is determined by the severity of the disease and the levels of certain antibodies in the blood.

The study will follow patients over a period to observe the effectiveness of the personalized treatment compared to the standard regimen. The goal is to determine if adjusting the treatment based on individual risk factors can better prevent the disease from returning. This research could lead to improved management strategies for patients with pemphigus, potentially offering a more tailored approach to their care.